159 related articles for article (PubMed ID: 38688429)
1. Excipient-related impurities in liposome drug products.
Wang C; Gamage PL; Jiang W; Mudalige T
Int J Pharm; 2024 May; 657():124164. PubMed ID: 38688429
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of cholesterol oxidation products and desmosterol in parenteral liposomal pharmaceutical formulations.
Wang C; Siriwardane DA; Jiang W; Mudalige T
Int J Pharm; 2019 Oct; 569():118576. PubMed ID: 31362094
[TBL] [Abstract][Full Text] [Related]
3. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
Wu Y; Levons J; Narang AS; Raghavan K; Rao VM
AAPS PharmSciTech; 2011 Dec; 12(4):1248-63. PubMed ID: 21948318
[TBL] [Abstract][Full Text] [Related]
4. Quantification of phospholipid degradation products in liposomal pharmaceutical formulations by ultra performance liquid chromatography-mass spectrometry (UPLC-MS).
Siriwardane DA; Wang C; Jiang W; Mudalige T
Int J Pharm; 2020 Mar; 578():119077. PubMed ID: 31988036
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation.
Van Haute D; Jiang W; Mudalige T
Int J Pharm; 2019 Oct; 569():118603. PubMed ID: 31401296
[TBL] [Abstract][Full Text] [Related]
6. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
[TBL] [Abstract][Full Text] [Related]
7. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
8. Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs.
Roberto de Alvarenga Junior B; Lajarim Carneiro R
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652589
[TBL] [Abstract][Full Text] [Related]
9. Elemental Impurities in Pharmaceutical Excipients.
Li G; Schoneker D; Ulman KL; Sturm JJ; Thackery LM; Kauffman JF
J Pharm Sci; 2015 Dec; 104(12):4197-4206. PubMed ID: 26398581
[TBL] [Abstract][Full Text] [Related]
10. Gamma sterilization of pharmaceuticals--a review of the irradiation of excipients, active pharmaceutical ingredients, and final drug product formulations.
Hasanain F; Guenther K; Mullett WM; Craven E
PDA J Pharm Sci Technol; 2014; 68(2):113-37. PubMed ID: 24668600
[TBL] [Abstract][Full Text] [Related]
11. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations.
Anderson M; Omri A
Drug Deliv; 2004; 11(1):33-9. PubMed ID: 15168789
[TBL] [Abstract][Full Text] [Related]
12. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
13. Polyoxylglycerides and glycerides: effects of manufacturing parameters on API stability, excipient functionality and processing.
Jannin V; Rodier JD; Musakhanian J
Int J Pharm; 2014 May; 466(1-2):109-21. PubMed ID: 24607211
[TBL] [Abstract][Full Text] [Related]
14. Impact of excipient interactions on solid dosage form stability.
Narang AS; Desai D; Badawy S
Pharm Res; 2012 Oct; 29(10):2660-83. PubMed ID: 22707362
[TBL] [Abstract][Full Text] [Related]
15. Integrity of liposomes in presence of cyclodextrins: effect of liposome type and lipid composition.
Hatzi P; Mourtas S; Klepetsanis PG; Antimisiaris SG
Int J Pharm; 2007 Mar; 333(1-2):167-76. PubMed ID: 17101248
[TBL] [Abstract][Full Text] [Related]
16. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
Padamwar MN; Pokharkar VB
Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
[TBL] [Abstract][Full Text] [Related]
17. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
Chadha R; Bhandari S
J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
[TBL] [Abstract][Full Text] [Related]
18. Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition.
Makabi-Panzu B; Gourde P; Désormeaux A; Bergeron MG
Cell Mol Biol (Noisy-le-grand); 1998 Mar; 44(2):277-84. PubMed ID: 9593578
[TBL] [Abstract][Full Text] [Related]
19. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
Holzgrabe U
J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of microwave oven heating for prediction of drug-excipient compatibilities and accelerated stability studies.
Schou-Pedersen AM; Østergaard J; Cornett C; Hansen SH
Int J Pharm; 2015 May; 485(1-2):97-107. PubMed ID: 25746946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
